From Coverage to Activation: Designing the Commercial Systems That Win

What You’ll Learn

Most product launches do not underperform because coverage is weak, they underperform because we are still managing access as if coverage were the constraint. 

Formulary access is secured. Contracts are signed. Coverage dashboards signal green lights. Yet initiation lags, regional variability widens, and competitive share shifts quietly.

While coverage opens the door, execution determines who walks through it. That shift drives what can be defined as Access Activation Architecture.

The traditional commercialization model assumes coverage is the gating event: secure payer policy, activate the field, generate demand, measure uptake. This model worked when coverage was the primary barrier. Today, coverage is rarely the binding constraint. Execution is.

More than 95% of Medicare Part D plans require prior authorization for specialty drugs, and denial rates for certain high-cost therapies exceed 25%.^[1-2] Physicians report spending nearly two full business days each week managing authorization requirements.^[3] Administrative burden now sits squarely inside clinical workflow. The result is predictable: revenue curves soften despite strong coverage, and the root cause is misdiagnosed as demand rather than execution.

Brands can secure favorable coverage and still struggle with treatment initiation. Providers may support a therapy clinically yet hesitate operationally. Patients may receive approval yet abandon therapy due to cost ambiguity or unclear coordination between drug acquisition and administration.^[4] Abandonment tied to affordability and authorization hurdles can exceed 50% in some specialty categories.^[4-5]

In markets where clinical differentiation narrows, operational reality becomes the deciding factor. The therapy that is easier to authorize, schedule, and coordinate within the practice workflow is the therapy that gains the most share.

What Is Access Activation Architecture?

Access Activation Architecture reflects the shift of market access from a contracting function to a coordinated commercial capability. It integrates payer intelligence, channel strategy, digital experience, and field enablement to remove administrative delays between coverage approval and therapy initiation and sustain adherence over time.

Its focus is precise: the period after contracting and before therapy reaches the patient. This is where revenue variability hides.

In oncology and other specialty categories where time-to-therapy influences both outcomes and competitive position, operational simplicity becomes decisive. When products are clinically comparable, the therapy that integrates most seamlessly into real-world practice prevails.

Across ongoing client engagements in oncology, rare disease, and emerging specialty markets, one pattern is consistent. Performance variability rarely correlates with coverage strength alone. Instead, it correlates with how well the system functions after coverage is secured. Coverage is visible. System design is not.

Payer Intelligence as Decision Architecture

Traditional payer intelligence tracks coverage criteria and step edits. Modern payer intelligence must map the full decision architecture that shapes how patients move from diagnosis to treatment.

Precision oncology illustrates this clearly. Treatment eligibility depends on biomarker sequencing and diagnostic adoption. If the biomarker test is not covered but the drug is, the patient never reaches therapy despite a favorable drug policy. This disconnect often arises when diagnostic and drug coverage are evaluated independently within payer systems.

66% of oncology providers cite insurance coverage as a meaningful barrier to biomarker testing.^[6] Regulatory approval alone does not guarantee utilization when diagnostic pathways are misaligned. The first barrier often emerges upstream, at testing.

In precision oncology, drop-off frequently occurs before therapy is even considered. Eligible patients are missed because biomarker testing is delayed or results are not integrated into treatment workflows. In recent engagements, surfacing this diagnostic-to-treatment disconnect early allowed launch strategy to incorporate payer education on testing coverage, structured biomarker resources, and clearer sequencing guidance. When those elements aligned, initiation variability narrowed, and more biomarker-positive patients moved efficiently to therapy. When diagnostic alignment, institutional pathway inclusion, and workflow sequencing are misaligned, coverage becomes a hollow metric.

This dynamic extends beyond precision oncology. In therapeutic areas where patient identification depends on diagnostics or evolving care pathways, the reimbursement strategy must address the full diagnostic-to-treatment continuum.

MASH (metabolic dysfunction-associated steatohepatitis) demonstrates the same principle. Madrigal’s strategy extended beyond drug coverage to align diagnostics, payer education, and care pathway processes. Within two quarters, the therapy achieved approximately 80% commercial coverage.^[7] Diagnostic alignment and payer integration likely contributed to early uptake. 

Downstream, the decision environment becomes even more layered.

Integrated delivery networks (IDNs) and organized customers increasingly manage utilization through internal clinical pathways that operate alongside formal payer policy.^[8] These committees function as shadow formularies, shaping therapeutic preference based on total cost-of-care and site-of-care economics.^[9] A therapy can secure favorable health-plan coverage yet face institutional deprioritization within large systems.

In complex specialty categories, this dynamic has translated into strong coverage metrics paired with uneven institutional uptake. In many IDNs, pathway positioning matters more than payer status. Ignoring that layer does not eliminate it—it simply makes it harder to explain the variability later.

Channel Strategy as Competitive Positioning

Channel strategy increasingly shapes real-world utilization.

Medically integrated dispensing (MID) continues to expand across oncology and allied specialties as consolidation and vertical integration reshape care delivery, particularly for pharmacy benefit products.^[10] When dispensing is embedded within the practice and supported by EMR visibility and coordinated care teams, time-to-treatment shortens, and administrative handoffs decrease. What begins as an operational improvement often can strengthen account preference and continuity of care. 

In oncology access strategy work underway, precision-focused brands are expanding integrated dispensing ahead of less differentiated competitors by aligning channel strategy with accounts that can support high-quality MID infrastructure. Contracting prioritizes operational readiness, and field communication reinforces workflow integration.

This approach embeds therapy within the practice’s economic and operational structure. Initiation becomes more consistent, adherence improves, and switching risk declines before competitive entrants gain traction.

A similar dynamic is emerging in chronic and consumer-influenced categories through direct-to-patient (DTP) and hybrid fulfillment models. Enterprise DTP ecosystems combine telehealth access, transparent pricing, savings programs, and fulfillment services. Together, these elements shorten the path from approval to first dose. For obesity therapies and other consumer-driven medications, this approach improves prescription initiation and addresses affordability earlier in the treatment journey.^[11-12]

Across both MID and DTP models, channel is no longer simply about where the product is dispensed—it shapes how consistently the therapy is initiated, how predictably it is reimbursed, and how difficult it is for competitors to displace. Simply put, when clinical differentiation narrows, the product that is operationally embedded within the account wins.

Digital as Activation Infrastructure

Administrative burden and cost ambiguity remain leading contributors to therapy abandonment.^[4-5] Digital platforms must function as operational infrastructure rather than promotional channels.

Patients and providers expect clarity around coverage criteria, anticipated out-of-pocket costs, and coordination steps between drug procurement and administration. When digital ecosystems fail to reflect reimbursement realities or real-world workflow, confusion increases and delays follow.

In infectious disease work currently underway, a structured digital engagement tool is being developed to guide patients and providers through the access pathway in a sequenced and intuitive manner. It is being designed to deliver personalized coverage insights, anticipated cost considerations, and coordinated steps between drug procurement and administration. By consolidating documentation requirements, reimbursement guidance, and support resources into one coherent experience, administrative burden declines and confidence in starting therapy improves.

As this model evolves, digital platforms will increasingly incorporate predictive signals to identify risk earlier in the process. Denial patterns, documentation gaps, and workflow bottlenecks can be surfaced before they translate into abandonment. Organizations that deliberately integrate digital with payer strategy and field execution gain earlier visibility into where performance may stall and the opportunity to intervene before revenue is affected.

Field Enablement as Implementation Confidence

Field enablement must support implementation, not simply amplify messaging.

In malignant hematology, the introduction of bispecific therapies exposed a predictable challenge. Adoption slowed in community oncology settings, not because of skepticism about the data but because of operational uncertainty. Prior authorization sequencing across multi-component regimens, inpatient step-up dosing followed by outpatient continuation, and coordination around toxicity management required alignment across hospital and community sites of care.^[13]

Clinical value was clear. Execution pathways were not.

In ongoing complex therapy engagements, structured collaboration between medical affairs and commercial teams has focused on aligning scientific exchange with practical implementation. Medical supports education on biomarker integration, development of clinical care pathways, and adverse event management within compliant boundaries. Commercial reinforces reimbursement sequencing, benefit-verification processes, site-of-care considerations, and patient-support infrastructure.^[14]

When field teams are equipped with resources that reflect real-world reimbursement requirements and care coordination constraints, conversations shift. Instead of debating differentiation, providers focus on operationalizing therapy within their practices. Initiation becomes more consistent because uncertainty around sequencing, documentation, and site-of-care logistics declines.

From Coverage to Competitive Advantage

Treating execution as a commercial discipline requires governance, shared accountability, and new performance metrics. Coverage percentage alone does not explain performance variability. Diagnostic-to-treatment lag, days from authorization approval to first dose, institutional pathway positioning, and early abandonment after approval provide a clearer view of whether the commercial system is working. These indicators cut across market access, medical, commercial operations, digital, and field teams. Organizations structured in silos often recognize variability only once it appears in prescription data, and by then, intervention is reactive and more difficult.

When performance varies by account, it is rarely accidental. It reflects how the system was designed.

Strong execution connects diagnostic alignment, channel configuration, digital infrastructure, and field readiness into one coordinated model. Payer strategy anticipates institutional decision points before they suppress uptake. Channel design reinforces reimbursement predictability and site-of-care alignment. Digital tools reduce documentation confusion and cost surprises. Field teams are equipped to navigate sequencing, authorization requirements, and implementation realities with confidence.

But no single function owns this challenge. Not payer strategy. Not digital. Not medical affairs. Not the field. Each sees part of the problem. Few see the system.

In markets defined by authorization intensity, institutional governance, and narrowing clinical differentiation, leadership is determined by how deliberately organizations design for execution. Contract negotiations secure eligibility. System design secures leadership. The organizations that win will be those that build systems capable of consistently converting policy into patient starts.

Most organizations manage diagnostic alignment, institutional engagement, reimbursement sequencing, digital experience, and field readiness in parallel. Variability appears long before it is recognized as a structural issue.

This is where integration becomes decisive.

Klick brings together market access strategists, medical communicators, digital architects, and commercial leaders into a single, coordinated model. Aligning payer strategy, institutional engagement, channel configuration, digital experience, and field execution allows performance to be engineered deliberately rather than assumed.

The companies that design that system deliberately will not simply compete in their categories.

They will shape them.

That is Access Activation Architecture.

References

Klick Health is the world’s largest independent commercialization partner for life sciences and a leading full-service pharma marketing partner, serving as agency of record for leading pharma, biotech, and healthcare brands. Klick’s specialized offerings are rooted in deep medical and scientific understanding, including market insights, award-winning creative, and proprietary AI and data models to craft impactful brand narratives and seamless customer journeys. Backed by nearly 250 medical experts and advanced healthcare analytics, Klick delivers integrated marketing strategy and communications, from new product launch strategy to MLR review with real-world evidence, helping brands thrive in today’s complex healthcare landscape. Learn more at Klick.com.